Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0221 • ACR Convergence 2020
Should We Use BioDMARDS in First Intention in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort
Emilie Sapart¹, Tatiana Sokolova¹, Stéphanie de Montjoye¹, Stéphanie Dierckx², Adrien Nzeusseu Toukap³, Aleksandra Avramovska¹, Laurent Meric de Bellefon¹ and Patrick Durez⁴, ¹Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Rheumatology, CHU Mont-Godinne, Mont Godinne, Belgium, ³1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, ⁴Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Background/Purpose: Early effective treatment has led to major improvements in patients with rheumatoid arthritis (ERA). Low disease activity and remission are achieved earlier and in…
Abstract Number: 0238 • ACR Convergence 2020
Gestational Desire and Certolizumab Pegol in Patients with Chronic Inflammatory Rheumatic Disease. Preliminary Results of the GESTAMAD Cohort
Laura Gonzalez Hombrado¹, Marina Salido Olivares², Maria Carmen Ortega de la O³, Pilar Navarro Alonso⁴, Patricia Castro Perez⁵, Ana Castilla⁶, Alvaro Garcia Martos⁷, Celia Arconada³, Angel Aragon Diez⁸, Carolina Marin huertas³ and Eva Maria Andres Esteban⁹, ¹Hospital Universitario del Tajo, MADRID, Spain, ²Hospital de Parla, Madrid, Spain, ³Hospital infanta Elena, Madrid, Spain, ⁴Hospital de Fuenlabrada, Madrid, Madrid, Spain, ⁵Hospital Universitario de Getafe, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷Hospital Universitario del Tajo, Madrid, ⁸Hospital Universitario de Gerafe, Madrid, Spain, ⁹Rey Juan Carlos University, Madrid, Spain
Background/Purpose: INTRODUCTION The use of biological therapies during pregnancy has been contraindicated since the beginning of the use of these drugs. In recent years several…
Abstract Number: 0482 • ACR Convergence 2020
Differential Influence of CDAI Components Based on Disease State in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Edward C Keystone¹, Mohammad Movahedi², Angela Cesta³, Claire Bombardier⁴, John Sampalis⁵ and Emmanouil Rampakakis⁵, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, ON, Canada, ⁴Institute for Work and Health, Toronto, ON, Canada, ⁵JSS Medical Research, St-Laurent, QC, Canada
Background/Purpose: Treat-to-target recommendations for rheumatoid arthritis (RA) dictate that remission or low disease activity should be aimed. Although numerous composite indices are available, the clinical…
Abstract Number: 0576 • ACR Convergence 2020
Medical Savings of Timely Rheumatoid Arthritis Diagnoses
Kathryn Johnson¹, Christine Sawicki¹, Cristina Sotelo², Tanvi Kalevar³, Sylvie Lardeux⁴, Fabio Casadio³, David Baghdadi⁵, Michele Hamburger⁶, Elisea Avalos-Reyes⁷ and Kjel Johnson¹, ¹CVS Health, Lincoln, RI, ²CVS Health, Austin, TX, ³CVS Health, New York, NY, ⁴CVS Health, Wellesley, MA, ⁵CVS Health, Woonsocket, RI, ⁶Frances Hamburger Institute, Hauppauge, NY, ⁷CVS Health, Irving, TX
Background/Purpose: Previous studies suggest that early rheumatoid arthritis (RA) recognition and treatment provides greater clinical benefits than treatment started later in the disease course. However,…
Abstract Number: 0747 • ACR Convergence 2020
Isotope-Labeling-LC-MS-based Metabolic Profiling of Multiple Serum Sample Sets for the Discovery of High-confidence Rheumatoid Arthritis Biomarkers
Xiaohang Wang¹, Wei Han¹, Liang Li¹, Stephanie Wichuk², Edna Hutchings³, Rana Dadashova³, Joel Paschke³ and Walter Maksymowych², ¹Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is hampered by suboptimal accuracy of currently available serological biomarkers. In this work, we applied a high-performance chemical…
Abstract Number: 0764 • ACR Convergence 2020
Uncovering Novel Biomarkers for Rheumatoid Arthritis from Feature Selection and Machine Learning Approaches on Synovium and Blood Gene Expression Data
Dmitry Rychkov¹, Jessica Neely¹ and Marina Sirota¹, ¹UCSF, San Francisco, CA
Background/Purpose: There is an urgent need to develop objective biomarkers for early diagnosis and monitoring of disease activity in Rheumatoid arthritis (RA). Here we define…
Abstract Number: 0781 • ACR Convergence 2020
Phenotypic and Functional Characterisation of Synovial Fluid-derived Fibroblast-like Synoviocytes in Rheumatoid Arthritis
Ditte Køster¹, Johanne Hovgaard Egedal¹, Malene Hvid¹, Martin Roelsgaard Jakobsen¹, Ulf Müller-Ladner², Bent Deleuran¹, Tue Wenzel Kragstrup¹, Elena Neumann³ and Morten Aagaard Nielsen¹, ¹Aarhus University, Aarhus, Denmark, ²Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ³Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany
Background/Purpose: Fibroblast-like synoviocytes (FLS) are central cellular components in persistent inflammatory joint diseases such as rheumatoid arthritis (RA). Pathological subsets of FLS have been identified…
Abstract Number: 0798 • ACR Convergence 2020
A Randomized, Double-blind Phase 3 Study Comparing the Efficacy, Safety and Immunogenicity of PF-06410293 (Abrilada™), an Adalimumab (ADL) Biosimilar, and Reference ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92
Roy Fleischmann¹, Daniel Alvarez², Amy Bock³, Carol Cronenberger⁴, Ivana Vranic⁵, Wuyan Zhang⁶ and Rieke Alten⁷, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Pfizer, Collegeville, PA, ³Pfizer, Cambridge, MA, ⁴Pfizer, Collegeville, ⁵Pfizer, Tadworth, United Kingdom, ⁶Pfizer, New York, ⁷Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany
Background/Purpose: To evaluate the long-term safety, immunogenicity (IG), and efficacy of the adalimumab (ADL) biosimilar, PF-06410293 (ADL-PF), in patients (pts) with moderate to severe active…
Abstract Number: 0814 • ACR Convergence 2020
“I Want to Switch Back”: Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic
Rishi Gupta¹, Muhammad Shipa², Su-Ann Yeoh², Pauline Buck¹ and Michael Ehrenstein², ¹University College London Hospital, London, United Kingdom, ²University College London, LONDON, United Kingdom
Background/Purpose: During the COVID-19 pandemic, rapid guidelines by the National Institute for Health and Care Excellence (NICE) in the United Kingdom[1] recommended consideration of switching…
Abstract Number: 0831 • ACR Convergence 2020
Sociodemographic, Disease, and Medication Profile of RA Patients Under 65 Years Compared with 65 Years or Older at Registry Enrollment: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Age is an important factor that can affect disease course, physical function and treat to target strategy for patients with rheumatoid arthritis (RA). We…
Abstract Number: 0991 • ACR Convergence 2020
Pathogenic, Glycolytic PD-1+ B Cells Accumulate in the Hypoxic RA Joint
Achilleas Floudas¹, Nuno Neto², Viviana Marzaioli³, Kieran Murray⁴, Barry Moran⁵, Michael Monaghan⁶, Candice Low⁷, Ronan Mullan⁸, Navin Rao⁹, Vinod Krishna⁹, Sunil Nagpal¹⁰, Douglas Veale¹¹ and Ursula Fearon³, ¹Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Dublin, Ireland, ²Department of Mechanical and Manufacturing Engineering, Dublin, Dublin, Ireland, ³Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, ⁵Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁶Department of Mechanical and Manufacturing Engineering, Dublin, Ireland, ⁷EULAR Centre for Arthritis and Rheumatic diseases, St Vincents University Hospital, UCD, Dublin, Ireland, ⁸Adelaide and Meath Hospital, Dublin, Dublin, Ireland, ⁹Janssen R&D, Spring House, PA, ¹⁰Janssen Research & Development, Collegeville, PA, ¹¹EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid arthritis (RA) often has a progressive and debilitating course, with significant impact on the patient’s quality of life. Despite the long-known association with…
Abstract Number: 1012 • ACR Convergence 2020
The Global Prevalence of Rheumatoid Arthritis: A Meta-Analysis
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen¹ and Charles Inderjeeth¹, ¹The University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: To determine the global population prevalence of rheumatoid arthritis (RA) based on published studies and assess factors that influence RA prevalence estimates.Methods: Four electronic…
Abstract Number: 1183 • ACR Convergence 2020
Factors Associated with Incident Heart Failure Subtypes in Patients with Rheumatoid Arthritis Using Electronic Health Record Data
Sicong Huang¹, Tianrun Cai¹, Brittany Weber¹, Zeling He¹, Kumar Dahal¹, Chuan Hong², Andrew Cagan³, Jacob Joseph⁴, Seoyoung Kim¹, Daniel H Solomon¹, Tianxi Cai² and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School; Harvard T.H. Chan School of Public Health, Boston, MA, ³Partners Healthcare, Somerville, MA, ⁴Brigham and Women's Hospital; Veterans Affairs Boston Healthcare System, Boston, MA
Background/Purpose: Heart failure (HF) is a major cause of mortality in rheumatoid arthritis (RA) and is broadly categorized into two subtypes, each with distinct pathophysiology:…
Abstract Number: 1199 • ACR Convergence 2020
Prevalence of Subclinical Interstitial Lung Disease After a Mean Rheumatoid Arthritis Duration of 13 Years: Results from the French ESPOIR Cohort
Pierre-Antoine Juge¹, Marie-Pierre Debray², Esther Ebstein¹, Raphaël Borie³, Arnaud Constantin⁴, Bernard Combe⁵, Bruno Fautrel⁶, Rene-Marc Flipo⁷, Xavier Mariette⁸, Olivier Vittecoq⁹, Alain Saraux¹⁰, Guillermo Carvajal Alegria¹¹, Jean Sibilia¹², Francis Berenbaum¹³, Bruno Crestani³ and Philippe Dieude¹⁴, ¹Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²Université de Paris, Service de Radiologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ³Université de Paris, Service de Pneumologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ⁴Hospital Pierre Paul Riquet, Toulouse, France, ⁵University of Montpellier, Montpellier, France, ⁶Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁷Lille University Hospital, Lille, France, ⁸Paris-Sud University, Rueil-Malmaison, France, ⁹University Hospital of Rouen, Rouen, France, ¹⁰Department of Rheumatology, UBO, CHU, INSERM 1227 (LBAI), Brest, France, ¹¹CHU de Brest, Service de Rhumatologie, Brest, France, ¹²Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, France, ¹³AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ¹⁴Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Interstitial lung disease (ILD) is a frequent extra-articular manifestation of rheumatoid arthritis (RA). It is associated with a high morbi-mortality. However, the exact prevalence…
Abstract Number: 1215 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
David Walker¹, Tsutomu Takeuchi², Beatrix Bartok³, Shangbang Rao³, I-Heng Lee⁴, Robin Besuyen⁵, Jacques-Eric Gottenberg⁶ and Mark Genovese³, ¹Northumbria Healthcare Trust, North Shields, United Kingdom, ²Keio Univ School of Medicine, Tokyo, Japan, ³Gilead Sciences, Inc., Foster City, CA, ⁴Gilead Sciences, Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶Strasbourg University Hospital, Strasbourg, France
Background/Purpose: EULAR guidelines recommend a treat-to-target approach focusing on reducing inflammation to prevent joint damage, physical disability, and mortality.1 However, patients consider reduction in pain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].